Cambridge Antibody Technology appoints new ceo

Published: 23-Jun-2006

AstraZeneca's recommended offer to acquire Cambridge Antibody Technology (CAT) has been declared unconditional and the CAT Group will now form part of the AstraZeneca group of companies.


AstraZeneca's recommended offer to acquire Cambridge Antibody Technology (CAT) has been declared unconditional and the CAT Group will now form part of the AstraZeneca group of companies.

Dr Hamish Cameron has been appointed as a director and ceo of CAT Ltd, with immediate effect. He joins CAT following a number of senior r&d appointments in AstraZeneca, including head of the cardiovascular therapy area and head of medical research.

"The acquisition of CAT indicates our intention of growing a leading biopharmaceuticals capability in AstraZeneca, led from CAT in Cambridge, which combines the biologics discovery and early development of CAT with AstraZeneca's global discovery, development and marketing expertise," said Dr John Patterson, executive director of development at AstraZeneca and chairman of the new CAT Ltd board. "The biopharmaceuticals capability will be distinct from, but complementary to, AstraZeneca's small molecule franchise."

You may also like